Stocks News

LAST PRICE
134.0000
TODAY'S CHANGE (%)
Trending Up1.3400 (1.0101%)

Bid / Lots
132.7800/ 4
Ask / Lots
134.0000/ 2
Open / Previous Close
134.0000 / 132.6600
Day Range
Low 133.9700
High 134.0000
52 Week Range
Low 55.2500
High 159.8900
Volume
7,222

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- DJ Sarepta Therapeutics Raised to Outperform From Perform by Oppenheimer, from 8:34AM ET on Tuesday May 14, 2024 by Dow Jones
  8:34AM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: SRPT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/SRPT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 14, 2024 08:34 ET (12:34 GMT)
- Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180, from 7:30AM ET on Tuesday May 14, 2024 by MT Newswires
  7:30AM ET on Tuesday May 14, 2024 by MT Newswires
  Companies Mentioned: SRPT
  07:30 AM EDT, 05/14/2024 (MT Newswires) -- Sarepta Therapeutics (SRPT) has an average rating of outperform and price targets ranging from $128 to $224, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic r...
May 3, 2024
- DJ Sarepta Therapeutics Is Maintained at Overweight by JP Morgan, from 3:02PM ET on Friday May 03, 2024 by Dow Jones
  3:02PM ET on Friday May 03, 2024 by Dow Jones
  Companies Mentioned: SRPT
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/SRPT/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 03, 2024 15:02 ET (19:02 GMT)
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health, from 10:07AM ET on Friday May 03, 2024 by Dow Jones
  10:07AM ET on Friday May 03, 2024 by Dow Jones
  Companies Mentioned: SRPT
  
  -- TIME recognizes Dr. Mendell's decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy, including the first gene therapy for Duchenne muscular dystrophy
- Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health, from 10:07AM ET on Friday May 03, 2024 by Business Wire
  10:07AM ET on Friday May 03, 2024 by Business Wire
  Companies Mentioned: SRPT
  Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propelled a new age of treatment for several genetic diseases, including Duchenne muscular dystrophy.

Yesterday
- Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing, from 17 hours ago by MT Newswires
  17 hours ago by MT Newswires
  Companies Mentioned: MEDP
- Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by PR Newswire
  8:30AM ET on Tuesday May 14, 2024 by PR Newswire
  Companies Mentioned: NBIX
May 13, 2024
- Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test, from 4:18AM ET on Monday May 13, 2024 by MT Newswires
  4:18AM ET on Monday May 13, 2024 by MT Newswires
  Companies Mentioned: QGEN
May 9, 2024
- Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024, from 9:45AM ET on Thursday May 09, 2024 by PR Newswire
  9:45AM ET on Thursday May 09, 2024 by PR Newswire
  Companies Mentioned: NBIX
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults, from 8:30AM ET on Thursday May 09, 2024 by PR Newswire
  8:30AM ET on Thursday May 09, 2024 by PR Newswire
  Companies Mentioned: NBIX
May 8, 2024
- Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 4:54PM ET on Wednesday May 08, 2024 by MT Newswires
  4:54PM ET on Wednesday May 08, 2024 by MT Newswires
  Companies Mentioned: MEDP
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults, from 8:30AM ET on Wednesday May 08, 2024 by PR Newswire
  8:30AM ET on Wednesday May 08, 2024 by PR Newswire
  Companies Mentioned: NBIX
May 7, 2024
- Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference, from 4:15PM ET on Tuesday May 07, 2024 by PR Newswire
  4:15PM ET on Tuesday May 07, 2024 by PR Newswire
  Companies Mentioned: NBIX
- Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024, from 8:30AM ET on Tuesday May 07, 2024 by PR Newswire
  8:30AM ET on Tuesday May 07, 2024 by PR Newswire
  Companies Mentioned: NBIX
May 6, 2024
- Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring, from 8:30AM ET on Monday May 06, 2024 by PR Newswire
  8:30AM ET on Monday May 06, 2024 by PR Newswire
  Companies Mentioned: NBIX

Sarepta Therapeutics Inc
NASDAQ:SRPTUnited States

Search Criteria

Yesterday

DJ Sarepta Therapeutics Raised to Outperform From Perform by Oppenheimer, from 8:34AM ET on Tuesday May 14, 2024 by Dow Jones

Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180, from 7:30AM ET on Tuesday May 14, 2024 by MT Newswires

May 3, 2024

DJ Sarepta Therapeutics Is Maintained at Overweight by JP Morgan, from 3:02PM ET on Friday May 03, 2024 by Dow Jones

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health, from 10:07AM ET on Friday May 03, 2024 by Dow Jones

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health, from 10:07AM ET on Friday May 03, 2024 by Business Wire

Peers Headlines

Yesterday

Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing, from 17 hours ago by MT Newswires

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by PR Newswire

May 13, 2024

Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test, from 4:18AM ET on Monday May 13, 2024 by MT Newswires

May 9, 2024

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024, from 9:45AM ET on Thursday May 09, 2024 by PR Newswire

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults, from 8:30AM ET on Thursday May 09, 2024 by PR Newswire

May 8, 2024

Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing, from 4:54PM ET on Wednesday May 08, 2024 by MT Newswires

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults, from 8:30AM ET on Wednesday May 08, 2024 by PR Newswire

May 7, 2024

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference, from 4:15PM ET on Tuesday May 07, 2024 by PR Newswire

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024, from 8:30AM ET on Tuesday May 07, 2024 by PR Newswire

May 6, 2024

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring, from 8:30AM ET on Monday May 06, 2024 by PR Newswire